Follow-on biologics [electronic resource] : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.

By: United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions
Material type: TextTextSeries: United States. S. hrg: 110-375.Publisher: Washington : U.S. G.P.O., 2008Description: 1 electronic text (iv, 78 pages) : HTML, digital, PDF fileContent type: text Media type: computer Carrier type: online resourceSubject(s): Drug development -- Government policy -- United States | Pharmaceutical biotechnology -- Government policy -- United States | Pharmaceutical biotechnology -- United States -- Patents | Pharmaceutical technology -- Government policy -- United StatesGenre/Form: Patents. Additional physical formats: Follow-on biologics; Follow-on biologicsOnline resources: PDF version: Access document | Text version: Access document
Item type Current location Collection Call number Status Date due Barcode Item holds
Digital Government Document Rutgers University
Electronic Resource
Electronic Resource Available
Total holds: 0

Paper version available for sale by the Supt. of Docs., U.S. G.P.O.

Title from title screen (viewed on Nov. 17, 2008)

Includes bibliographical references.

Mode of access: Internet from the GPO Access web site.

Please contact Law Library staff with any questions about locating library materials.